Related Experiment Video
Updated: May 31, 2026
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
T cell therapy for nasopharyngeal carcinoma
1Pediatric Hematology/Oncology, Research Laboratories, and Medical Oncology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
Abstract:
Among the novel biologic therapeutics that will increase our ability to cure human cancer in the years to come, T cell therapy is one of the most promising approaches. However, with the possible exception of tumor-infiltrating lymphocytes therapy for melanoma, clinical trials of adoptive T-cell therapy for solid tumors have so far provided only clear proofs-of-principle to build on with further development. Epstein-Barr virus (EBV)-associated malignancies offer a unique model to develop T cell-based immune therapies, targeting viral antigens expressed on tumor cells. In the last two decades, EBV-specific cytotoxic T-lymphocytes (CTL) have been successfully employed for the prophylaxis and treatment of EBV-related lymphoproliferative disorders in immunocompromised hosts. More recently, this therapeutic approach has been applied to the setting of EBV-related solid tumors, such as nasopharyngeal carcinoma. The results are encouraging, although further improvements to the clinical protocols are clearly necessary to increase anti-tumor activity. Promising implementations are underway, including harnessing the therapeutic potential of CTLs specific for subdominant EBV latent cycle epitopes, and delineating strategies aimed at targeting immune evasion mechanisms exerted by tumor cells.
Insights
T cell therapy shows promise for treating solid tumors, particularly Epstein-Barr virus (EBV)-associated cancers. Current EBV-specific cytotoxic T-lymphocyte (CTL) therapies are effective but require further optimization for enhanced anti-tumor activity.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- T cell therapy is a promising biologic treatment for human cancers.
- Adoptive T-cell therapy for solid tumors has shown proof-of-principle but needs further development.
- Epstein-Barr virus (EBV)-associated malignancies provide a model for T cell-based therapies targeting viral antigens.
Purpose of the Study:
- To review the application of EBV-specific cytotoxic T-lymphocytes (CTL) in treating EBV-related malignancies.
- To highlight the successes and limitations of current EBV-CTL therapies.
- To discuss future directions for improving T cell-based cancer immunotherapy.
Main Methods:
- Review of clinical trials and therapeutic strategies involving EBV-specific CTLs.
- Analysis of the efficacy of CTL therapy in EBV-related lymphoproliferative disorders and solid tumors.
- Exploration of novel approaches to enhance anti-tumor activity.
Main Results:
- EBV-specific CTLs have been successfully used for prophylaxis and treatment of EBV-related lymphoproliferative disorders in immunocompromised individuals.
- Application of EBV-CTL therapy to EBV-related solid tumors, like nasopharyngeal carcinoma, shows encouraging results.
- Current therapies require improvements to increase anti-tumor efficacy.
Conclusions:
- EBV-specific CTL therapy is a viable approach for EBV-associated cancers.
- Future strategies include targeting subdominant EBV epitopes and overcoming tumor immune evasion.
- Optimizing clinical protocols is essential for advancing T cell-based cancer immunotherapy.
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...